ClinicalTrials.gg
RecruitingNCT07658898Updated Aug 21, 2026

dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia

An interventional study of Temporal Interference Stimulation and Sham Temporal Interference Stimulation in Schizophrenia Disorder, sponsored by Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 252 studies in Schizophrenia with a site in China — 64 open to participants now, 68 under way, 4 of them phase 3. Schizophrenia · China.

Planned enrollment
140th of 216
74 · median 100
Started
2026
with 25 others
No phase
110 of 252
36 open now
Primary completion
2027-12
later than 48 of 67 live
Registered
233rd of 252
by date

Among the 252 studies in Schizophrenia with a site in China, this one is the 140th largest by planned enrollment of the 216 interventional ones that give a count, is one of 26 that started in 2026, is one of 110 with no phase, reaches primary completion later than 48 of the 67 other live ones, and was the 233rd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

64 of the 252 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Schizophrenia with a site in China, or all of them as a file.
02

Study summary

This randomized, double-blind, sham-controlled trial aims to evaluate the efficacy and safety of dorsal anterior cingulate cortex-targeted temporal interference stimulation in individuals with schizophrenia. Participants will be randomly assigned to receive either active or sham stimulation for 10 sessions over two consecutive weeks. The primary outcome is the change in negative symptoms, assessed using the Negative Symptom Subscale of the Positive and Negative Syndrome Scale. Cognitive performance, detailed dimensions of negative symptoms, psychosocial functioning, quality of life, and treatment-related adverse events will also be evaluated. Neuroimaging assessments will be conducted before and after the intervention to explore potential neural mechanisms underlying the clinical effects of temporal interference stimulation.

Read the detailed description

Background and Scientific Rationale Persistent negative symptoms and cognitive difficulties remain major barriers to recovery in schizophrenia, often showing insufficient improvement with standard antipsychotic treatments. Transcranial temporal interference stimulation (tTIS) represents a novel non-invasive neuromodulation technique capable of reaching deeper brain structures without direct activation of overlying superficial cortical tissue. This trial focuses on targeting the dorsal anterior cingulate cortex (dACC), a critical node in the prefrontal-cingulate-striatal network involved in cognitive control, performance monitoring, and motivational processes. Study Design and Participants This study is a parallel-group, participant- and outcome-assessor-blinded, sham-controlled randomized clinical trial. A total of 74 eligible participants with a confirmed diagnosis of schizophrenia, who exhibit clinically meaningful negative symptoms and objective cognitive impairment, will be enrolled. Participants will be randomly assigned in a 1:1 ratio to receive either active dACC-targeted tTIS or sham stimulation.

ntervention ProceduresActive tTIS: Stimulation is delivered via a NervioX-1000 stimulator using two scalp electrode pairs targeting the dACC. The system applies two high-frequency carrier currents (2000 Hz and 2006 Hz) to generate a lower-frequency 6-Hz amplitude-modulated envelope field at the target region. Current intensity is titrated to participant tolerance and does not exceed 3.6 mA per channel. The treatment course consists of ten 30-minute sessions administered on consecutive weekdays over two weeks. Sham tTIS: The control group receives a sensory-matched simulation utilizing identical electrode montages and visit schedules. To ensure the integrity of the double-blind design, the sham condition features only brief ramp-up and ramp-down periods at the beginning and end of the session to mimic the transient scalp sensations of active treatment, with no continuous current delivered in between. Individualized Optimization: Prior to the intervention, participant-specific finite-element head models are derived from T1-weighted anatomical MRI scans to optimize dACC targeting, guiding candidate electrode positions and electric-field distributions.

Assessments and Outcomes Comprehensive evaluations are conducted at three specific time points: before the first stimulation session (baseline/T0), immediately after the 10-session treatment course (T1), and 4 weeks after treatment completion (T2). Primary Endpoint: The primary objective is to evaluate the change in negative symptom severity, operationalized as the clinician-rated Positive and Negative Syndrome Scale negative symptom subscale (PANSS-NS) score. Secondary Clinical Endpoints: Key secondary measures include overall neurocognitive functioning assessed by the Brief Assessment of Cognition in Schizophrenia (BACS) composite z-score and the dimensional structure of negative symptoms via the Scale for the Assessment of Negative Symptoms (SANS) total score. Broader evaluations incorporate measures of general psychopathology, apathy, anhedonia, social functioning, depression, anxiety, and sleep quality. Behavioral Tracking: Cognitive control, conflict processing, and response inhibition are objectively quantified using computerized Go/No-Go paradigms and the Stroop color-word task. Mechanistic Neuroimaging Exploration: Resting-state functional MRI (rs-fMRI) and diffusion tensor imaging (DTI) data are acquired pre- and post-intervention. These exploratory analyses aim to investigate treatment-related neural changes, tracking alterations in spontaneous brain activity and structural/functional connectivity to provide preliminary evidence of circuit-level mechanisms.

03

Conditions studied

  • Schizophrenia Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All of the following criteria must be satisfied for enrolment:

    1. A confirmed diagnosis of schizophrenia established according to the criteria set forth in the , Fifth Edition (DSM-5);
    2. Age between 18 and 65 years, regardless of sex, with completion of at least junior secondary education and the capacity to undergo neurocognitive testing;
    3. negative symptoms, operationalized as a PANSS negative symptom subscale (PANSS-NS) total score ≥ 20 with a rating of ≥ 3 on a minimum of one individual PANSS-NS item ; the PANSS positive symptom subscale score must additionally not exceed 19;
    4. Objective cognitive impairment evidenced by an age- and sex-adjusted composite z-score of ≤ -1.0 on the Chinese version of the Brief Assessment of Cognition in Schizophrenia (BACS), reflecting performance at least one standard deviation below normative values derived from Mandarin-speaking populations;
    5. Maintenance on an unchanged antipsychotic regimen - with no modification to medication type or dose - for at least 30 days prior to and continuing throughout the trial;
    6. Voluntary agreement to participate, documented by written informed consent following thorough explanation of study objectives and procedures; where applicable, a legally authorized representative may provide or co-sign consent.

Exclusion criteria

Exclusion Criteria:

  • Individuals will be ineligible if any of the following conditions apply:

    1. A concurrent psychiatric diagnosis requiring active clinical management, including but not limited to major depressive episode or bipolar disorder, or the presence of a comorbid neurological disorder or serious physical illness;
    2. Current or past substance use disorder, encompassing problematic consumption of alcohol or illicit substances;
    3. A documented seizure disorder or marked electroencephalographic abnormalities, particularly epileptiform activity;
    4. Evidence of structural brain pathology, including organic lesions, prior traumatic brain injury, or previous neurosurgical intervention;
    5. Presence of ferromagnetic implants or any other to MRI or tTIS exposure, including intracranial metallic clips, implanted cardiac devices, or cochlear implants;
    6. Current use of or other pharmacological agents known to meaningfully alter cortical excitability;
    7. Prior exposure to any neuromodulatory intervention - including modified electroconvulsive therapy (MECT), repetitive transcranial magnetic stimulation (TMS), or transcranial direct current stimulation (tDCS) - within the 30 days preceding enrolment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Active tTIS

    Participants assigned to this arm will receive active transcranial temporal interference stimulation (tTIS) targeting the dorsal anterior cingulate cortex (dACC). The stimulation will be delivered using two scalp electrode pairs operating at 2000 Hz and 2006 Hz, resulting in a 6-Hz envelope frequency. Current intensity will be titrated to participant tolerance and will not exceed 3.6 mA per channel. The intervention will be administered for 30 minutes per session across 10 consecutive weekdays. Each session begins with a 10-second current ramp-up and ends with a 10-second ramp-down.

    Device: Temporal Interference Stimulation

  • Sham comparator
    Sham tTIS

    Participants assigned to this arm will receive sham transcranial temporal interference stimulation (tTIS). The sham condition will mirror the active intervention with respect to electrode montage, visit schedule, and session length (30 minutes per session across 10 consecutive weekdays). To reproduce the transient scalp sensations associated with treatment initiation and termination, brief ramp-up and ramp-down periods will be applied at the beginning and end of each visit. Between these two phases, no continuous current will be delivered.

    Device: Sham Temporal Interference Stimulation

Interventions

  • DeviceTemporal Interference Stimulation

    Participants will receive active temporal interference stimulation targeting the dorsal anterior cingulate cortex. Two high-frequency alternating currents at 2000 Hz and 2006 Hz will be delivered using an individualized electrode configuration determined by electric field modeling. Each session will last 30 minutes. Treatment will be administered five times per week for two consecutive weeks, for a total of 10 sessions.

  • DeviceSham Temporal Interference Stimulation

    Participants will receive sham temporal interference stimulation using the same electrode placement and session schedule as the active stimulation group. Brief ramp-up and ramp-down periods will be applied to mimic the sensations associated with active stimulation, but sustained temporal interference stimulation will not be delivered. Each session will last 30 minutes. Treatment will be administered five times per week for two consecutive weeks, for a total of 10 sessions.

06

What researchers measure

Primary outcomes

  1. Change in the Positive and Negative Syndrome Scale Negative Symptom Subscale Score

    The Positive and Negative Syndrome Scale Negative Symptom Subscale (PANSS-NS) consists of 7 items. Each item is rated from 1 to 7, yielding a total score ranging from 7 to 49. Higher scores indicate greater severity of negative symptoms. The change from baseline to immediately after the intervention will be compared between the active and sham stimulation groups.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

Secondary outcomes

  1. Change in the Brief Assessment of Cognition in Schizophrenia Composite Score

    The Brief Assessment of Cognition in Schizophrenia (BACS) is a multidomain battery assessing overall neurocognitive functioning, including verbal learning and memory, working memory, psychomotor speed, verbal fluency, sustained attention and processing speed, and executive function. The constituent subtests include the List Learning Test, Digit Sequencing Task, Token Motor Task, Category Instances and Controlled Oral Word Association Test, Symbol Coding Task, and Tower of London Test. Domain scores are aggregated into a single composite z-score standardized against age- and sex-matched normative data. Lower values reflect greater cognitive impairment.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  2. Change in the Scale for the Assessment of Negative Symptoms Total Score

    The Scale for the Assessment of Negative Symptoms (SANS) provides a detailed characterization of negative symptomatology. It comprises 25 clinician-rated items spanning five domains: affective flattening or blunting, alogia, avolition-apathy, anhedonia-asociality, and attentional impairment. Each item is rated on a six-point scale ranging from 0 to 5. The item scores are summed to generate a total score, where higher values denote a more severe negative symptom profile.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  3. Change in the Apathy Evaluation Scale Total Scor

    The Apathy Evaluation Scale (AES-S) is a self-rated measure used to evaluate apathy. The scale consists of 18 items that probe the cognitive, affective, and behavioral dimensions of apathetic experiences over the preceding four weeks. Responses are summed to yield a total score ranging from 0 to 72. Higher scores indicate more severe apathy, meaning a worse outcome.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  4. Change in the Temporal Experience of Pleasure Scale Total Score

    The Temporal Experience of Pleasure Scale (TEPS) is used to evaluate hedonic experience by separately indexing the anticipatory and consummatory components of pleasure. The scale consists of 20 items, with each item rated on a six-point Likert scale ranging from 1 ("very false for me") to 6 ("very true for me"). Following the reverse-scoring of designated items, responses are summed to yield a total score, where lower values indicate greater anhedonia. Therefore, higher scores indicate a better outcome.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  5. Change in the Personal and Social Performance Scale Score

    The Personal and Social Performance Scale (PSP) is a clinician-administered tool used to evaluate real-world social functioning. It appraises four behavioral domains: engagement in socially constructive activities, interpersonal relationships, self-care, and disruptive or aggressive conduct. The total score spans from 1 to 100, with higher scores reflecting superior functional status.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  6. Change in the World Health Organization Quality of Life-BREF Score

    Subjective quality of life will be assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF). This multidimensional instrument covers four domains: physical health, psychological well-being, social relationships, and environment. Higher scores within each domain reflect a more positive self-reported quality of life, meaning a better outcome.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  7. Incidence of Treatment-Emergent Adverse Events

    The incidence and severity of adverse events will be assessed throughout the study period, from baseline to the 4-week follow-up, to evaluate treatment safety and tolerability.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  8. Change in Patient Health Questionnaire-9 (PHQ-9) Total Score

    Current depressive symptomatology will be quantified using the Patient Health Questionnaire-9 (PHQ-9). It contains nine items, each rated on a scale from 0 to 3, yielding an aggregate score ranging from 0 to 27. Elevated scores reflect a more severe depressive burden.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  9. Baseline Credibility/Expectancy Questionnaire (CEQ) Score

    Participants' perceptions of the credibility of the intervention and their expectations regarding treatment benefit will be assessed using an adapted version of the Credibility/Expectancy Questionnaire (CEQ). Higher scores indicate greater perceived credibility and higher expectations for treatment benefit, which represents a more positive expectancy.

    Time frame: Baseline before the first stimulation session

  10. Change in the Positive and Negative Syndrome Scale (PANSS) Total Score

    Broader psychopathological status will be assessed using the 30-item Positive and Negative Syndrome Scale (PANSS). Each of the 30 items is rated on a 1 to 7 ordinal scale, yielding a total score ranging from a minimum of 30 to a maximum of 210. Higher scores denote a more severe psychopathological profile, meaning a worse outcome.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  11. Change in Resting-State Functional Connectivity (rs-fMRI)

    Exploratory analyses will investigate treatment-related neural changes using resting-state functional MRI (rs-fMRI).

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  12. Change in Go/No-Go Task Accuracy

    Response inhibition will be evaluated with the computerized Go/No-Go paradigm. The derived index reported here is overall accuracy, calculated as the percentage of correct responses. Higher accuracy percentages indicate better response inhibition and cognitive control, meaning a better outcome.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  13. Change in Generalized Anxiety Disorder-7 (GAD-7) Total Score

    Anxiety over the preceding two weeks will be indexed by the Generalized Anxiety Disorder-7 scale (GAD-7). It comprises seven items, each scored from 0 to 3, which are summed to a maximum total score of 21. Higher totals denote greater anxiety severity.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  14. Change in Pittsburgh Sleep Quality Index (PSQI) Global Score

    Sleep disturbance will be quantified with the Pittsburgh Sleep Quality Index (PSQI). It is a 19-item self-report measure that generates a composite global score ranging from 0 to 21. Higher values indicate worse sleep quality.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  15. Change in Stroop Color-Word Task Interference Effect

    Conflict processing and cognitive control will be evaluated using the Stroop color-word task. The primary metric evaluated is the Stroop interference effect, calculated based on the differences in reaction times between congruent and incongruent trials. A lower interference effect score indicates better conflict processing and cognitive control, meaning a better outcome.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  16. Change in the Positive and Negative Syndrome Scale Positive Symptom Subscale Score

    The positive symptom subscale of the 30-item Positive and Negative Syndrome Scale (PANSS) will be evaluated to assess broader psychopathological status. Clinician-assigned ratings for the items in this subscale are each anchored on a 1 to 7 ordinal scale. Higher scores denote a more severe positive symptom profile, meaning a worse outcome.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

  17. Change in White Matter Structural Connectivity via Diffusion Tensor Imaging (DTI)

    Exploratory analyses will investigate treatment-related neural changes using diffusion tensor imaging (DTI). Changes in white matter structural connectivity will be evaluated to assess neural target engagement.

    Time frame: Baseline, immediately after the 2-week intervention, and at the 4-week follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 18 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 22, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07658898
Lead sponsor
Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University
Responsible party
Fan Wu (Attending Psychiatrist, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University) — Principal investigator
First posted
Jun 22, 2026
Start date
Jun 30, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Fan Wu
Contact
butterfly2402@163.com
86+17621766869
Hengfen Gong, MS
Contact
gonghf@shspdjw.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion